Baseline Hyperuricemia — And Why You Never Start Mid-Flare
A quick placeholder overview of baseline hyperuricemia and the flare rule.
- 6.8: Saturation threshold (mg/dL monosodium urate)
- <6.0: Treatment target (mg/dL serum urate)
- ~9.4: Typical baseline (mg/dL untreated gout)
- Avoid: Start-during-flare rule (wait for flare to resolve)
What hyperuricemia looks like
Serum urate sits above the solubility limit for long periods.
Why flares happen
Crystal shedding into joint fluid triggers acute inflammation.
Never initiate a xanthine oxidase inhibitor during an active flare.
Pre-treatment checklist
Confirm the flare has resolved before any dose is started.
Starting Dose Titration — The Low-Dose-Start Rule
A quick placeholder overview of the conservative starting-dose principle.
- 100 mg: Allopurinol start (lower in renal impairment)
- 40 mg: Febuxostat start (once daily)
- 2–5 wk: Re-check interval (before next dose step)
- ↑ transient: Flare risk on start (mobilization flares possible)
Why start low
Low starting doses reduce mobilization-flare risk during induction.
Flare prophylaxis
Low-dose colchicine or NSAID often bridges the titration period.
Start low, go slow — rapid urate drops can trigger flares.
Renal dose adjustment
Starting dose is lowered further with reduced kidney function.
Gradual Dose Escalation With Periodic Urate Re-Check
A quick placeholder overview of stepwise titration toward target.
- +50–100: Titration step size (mg allopurinol per step)
- 800 mg: Max allopurinol dose (per day, divided if needed)
- 80 mg: Max febuxostat dose (per day)
- ~4 wk: Recheck cadence (per titration step)
Stepwise increases
Dose rises in small increments until target urate is met.
Lab monitoring
Serum urate, renal function, and LFTs tracked each visit.
Escalate only after confirming urate above target on labs.
Adherence matters
Missed doses slow the approach toward the saturation line.
Target Reached — Serum Urate Sustainably Below 6 mg/dL
A quick placeholder overview of confirming a durable treat-to-target response.
- <6.0: Target threshold (mg/dL, general gout)
- <5.0: Tophi target (mg/dL, tophaceous disease)
- 2+: Confirmation checks (consecutive labs below target)
- >10%: Below-saturation margin (safety buffer at target)
Confirming target
Two consecutive labs below target confirm a durable response.
Holding the dose
The effective dose is locked in rather than pushed higher.
Target is a sustained level, not a single lucky reading.
Flare frequency drops
New flares become markedly less frequent once stabilized.
Maintenance Dosing & Gradual Dissolution of Stored Crystals
A quick placeholder overview of long-term maintenance and crystal clearance.
- Lifelong: Maintenance duration (in most chronic gout)
- Months–yrs: Tophi resolution (depends on crystal burden)
- Undersaturation: Dissolution driver (sustained below threshold)
- 1–2×: Annual urate checks (once stable on maintenance)
Why maintenance continues
Stopping therapy lets urate drift back above saturation.
Crystal dissolution kinetics
Stored crystals shrink slowly while urate stays undersaturated.
Deeper, sustained undersaturation dissolves crystal stores faster.
Long-term outcome
Tophi and flare frequency continue declining over years.